News of Note—Aeterna review, Allegro eye test and Ocugen orphan tag

Aeterna review, Allegro eye test and Ocugen orphan tag.

> Troubled Aeterna Zentaris, in the midst of a legal battle with its former CEO and major problems with its leading candidate, has announced a strategic review to “consider and evaluate various strategic and financing,” as well as “considering and recommending changes to the company’s management and governance.” Release

> Allegro Ophthalmics says the second stage of the phase 2b test of its leading eye drug Luminate hit its primary endpoint when used as a sequential therapy in patients with diabetic macular edema. Statement

> Ocugen says the FDA has been handed an orphan drug designation for its med OCU300 (brimonidine tartrate) in patients with ocular graft versus host disease. It works as a repurposed drug, which the biotech says can help up to 90% of patients “without significant side effects.” Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Belgian devicemaker Miracor Medical received a breakthrough designation from the FDA for its treatment designed to limit the damage of a heart attack.

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

Following an FBI raid and the replacement of its leadership, it’s come to light that the data behind uBiome’s microbiome test may contain flaws.